Opus Genetics (IRD) insider Joseph Schachle plans 15,625-share sale under Form 144

Rhea-AI Filing Summary

Joseph Schachle, associated with Opus Genetics, Inc., filed to sell company common stock through Raymond James & Associates on NASDAQ. The planned sale relates to a restricted stock unit (RSU) grant vesting dated July 22, 2026, with a planned cash transaction on July 23, 2026, covering 15,625 shares. The filing also lists a prior sale of 4,697 common shares for $24,519.00 on April 23, 2026.

Key Figures

Planned shares to be sold: 15,625 shares Prior shares sold: 4,697 shares Proceeds from prior sale: $24,519.00 +2 more

5 metrics

Planned shares to be sold 15,625 shares Common stock from RSU grant vest dated July 22, 2026, planned sale July 23, 2026

Prior shares sold 4,697 shares Common stock sale on April 23, 2026

Proceeds from prior sale $24,519.00 Consideration received for 4,697 common shares sold on April 23, 2026

Planned sale date 07/23/2026 Intended transaction date for 15,625 common shares on NASDAQ

RSU vesting date 07/22/2026 Restricted stock unit grant vest date for shares to be sold

Key Terms

Form 144, RSU Grant Vest, Common, NASDAQ

4 terms

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

RSU Grant Vest financial

"Common | 07/22/2026 | RSU Grant Vest | Issuer"

Common financial

"Common | 07/22/2026 | RSU Grant Vest | Issuer"

NASDAQ market

"82570000 | 07/23/2026 | NASDAQ"

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/23/2026 - 01:09 PM Accepted by SEC EDGAR 07/23/2026 - 01:09 PM Learn about SEC filing dates

FAQ

What does the Form 144 filing for IRD indicate about upcoming stock sales?

The Form 144 shows Joseph Schachle intends to sell 15,625 common shares of Opus Genetics, Inc. The shares are tied to an RSU grant vesting on July 22, 2026, with a planned cash sale on July 23, 2026 through Raymond James & Associates.

How many IRD shares are planned for sale in this Form 144?

The filing lists a planned sale of 15,625 common shares. These shares relate to an RSU grant vest dated July 22, 2026, and are expected to be sold for cash on July 23, 2026 via Raymond James & Associates on NASDAQ.

What prior IRD stock sales by Joseph Schachle are disclosed?

The filing discloses that on April 23, 2026, 4,697 common shares were sold for $24,519.00. This transaction is reported under securities sold during the past three months, providing context for recent trading activity in Opus Genetics, Inc. shares.

Which broker is involved in the planned IRD stock sale?

The planned sale of Opus Genetics, Inc. common stock uses Raymond James & Associates as broker. The broker’s address is listed in St. Petersburg, Florida, and the filing specifies that the transaction will occur on NASDAQ on July 23, 2026.

What is the source of the IRD shares being sold in this filing?

The shares come from an RSU Grant Vest recorded on July 22, 2026. The filing identifies the issuer as the source of these common shares, which are then scheduled for a cash sale on July 23, 2026 under this Form 144 notice.

Who is the reporting person in the IRD Form 144 and where are they based?

The reporting person is Joseph Schachle, listed care of Opus Genetics, Inc. at 8 Davis Drive, Durham, NC 27713. This address appears in the filer information section of the Form 144 notice relating to planned stock sales.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Raymond James & Associates 880 Carillon Parkway St. Petersburg FL 33716	4644	13653.36	82570000	07/23/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/22/2026	RSU Grant Vest	Issuer			15625	07/23/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
JOSEPH SCHACHLE c/o OPUS GENETICS, INC 8 DAVIS DRIVE Durham NC 27713	Common	04/23/2026	4697	24519.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)